Completed

Nicotinic Receptor Availability in Slow and Fast Nicotine Metabolizers

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Drug Data

Collected from today forward - Prospective
DrugDNA Samples
Who is being recruted

Mental Disorders+1

+ Substance-Related Disorders

+ Chemically-Induced Disorders

From 18 to 65 Years
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: October 2010
See protocol details

Summary

Principal SponsorUniversity of Pennsylvania
Last updated: June 16, 2017
Sourced from a government-validated database.Claim as a partner

Study start date: October 1, 2010

Actual date on which the first participant was enrolled.

The nicotine metabolite ratio (NMR), a stable marker of nicotine clearance rate, is a robust predictor of smoking relapse. Individuals who are fast nicotine metabolizers have higher rates of relapse, compared to slow metabolizers, on nicotine replacement or placebo treatment. Nicotine exerts its reinforcing properties, in part, by binding to α4β2* nicotinic acetylcholine receptors (nAChRs) in the brain. The α4β2* nAChRs are abundant and have high affinity for nicotine relative to other nAChR subtypes. The goal of this project is to identify abstinence-induced changes in neuronal nicotinic receptor availability that may underlie risk for smoking relapse. The investigators propose to utilize positron emission tomography (PET) imaging to examine the association of variation in nicotine metabolism with return to availability of α4β2* nAChRs during early abstinence. The investigators will measure α4β2* receptor availability using the PET radio-ligand 2-[18F]FA, administered with bolus injection, on two separate occasions: during smoking as usual and after 24 hours of abstinence. The proposed study will help us understand the neurochemical mechanisms that underlie the higher risk of relapse among faster nicotine metabolizers, thereby pointing to potential targets for tailored therapy for these smokers at increased risk. In addition, the investigators will invite six subjects who have completed the two PET scans described above to complete a third PET scan. During this third PET scan, the investigators plan to measure α4β2* receptor availability using the PET radio-ligand 2-[18F]FA, administered as bolus plus constant infusion after 24 hours of abstinence. The purpose will be to compare α4β2* nAChR binding potential data from the bolus 2-[18F]FA infusion protocol used in the main study to the bolus plus constant infusion protocol used in this third PET scan. The protocol of this third PET scan will help the investigators demonstrate the feasibility at the University of Pennsylvania of administering the radiotracer as a bolus plus constant infusion, and the feasibility of scanning for two hours (versus one hour in the current protocol) paradigm. This data is important pilot data for future NIH grant submissions using this radiotracer.

NCT01704573
Principal SponsorUniversity of Pennsylvania
Last updated: June 16, 2017
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

20 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Mental DisordersSubstance-Related DisordersChemically-Induced DisordersTobacco Use Disorder

Criteria

Inclusion Criteria: Ages 18 to 65 years old. Smoke 10 cigarettes per day for the previous 6 months. Weigh less than 300lbs (due to limitations of the PET and MRI scanners). Exclusion Criteria: Smoking behavior: Current enrollment or plans to enroll in a smoking cessation program, or use other smoking cessation medications in the next 2 months. Provide a CO reading of less than 10 ppm at medical screening. Alcohol/Drugs: History of substance abuse and/or currently receiving treatment for substance abuse (e.g., alcohol, opioids, cocaine, marijuana, or stimulants). Positive drug screen at any of the sessions (see page 8 for list of drugs and/or contra-indicated medications). Current alcohol consumption that exceeds 25 standard drinks/week. Providing a breath alcohol concentration (BrAC) reading of greater than or equal to 0.01 at any session. Medical: Women who are pregnant, planning a pregnancy, or lactating; all female subjects shall undergo a serum pregnancy test at the medical screening session and urine pregnancy tests at the two PET scans and MRI scan. Women of child-bearing age must agree in writing to use an approved method of contraception or agree to abstain from sexual intercourse History or current diagnosis of the following psychiatric diagnoses identified by the MINI (Mini International Neuropsychiatric Interview) such as psychosis, bipolar disorder, schizophrenia, major current depression, or any Axis 1 disorder Self-report of serious or unstable disease within the past 6 months (e.g., cancer [except melanoma], HIV/AIDS, stroke, angina, coronary disease, heart attack). History of epilepsy or a seizure disorder. Any medical or neurological condition that might interfere with the distribution of the radiotracer as determined by the study M.D. Medication: a. Current use or recent discontinuation (within last 14-days) of the following medications: Any form of smoking cessation medication (Zyban, Wellbutrin, Wellbutrin SR, Chantix, NRT); Recent (within last 14 days) or planned use of psychotropic medications (anti-psychotics, anti-depressants, anti-anxiety, anti-panic medications, mood stabilizers, opioids, and stimulants). Participants shall be instructed to refrain from using any study prohibited drugs (note - participants are allowed to take prescription medicines not in the exclusion list) throughout their participation in the study. Imaging-Related Exclusion Criteria: Self-reported history of head trauma or brain (or CNS) tumor. Self-reported history of claustrophobia (contraindicated for PET and MRI). Having a cochlear implant or wearing bilateral hearing aids. Self-reported use of pacemakers, certain metallic implants, or presence of metal in the eye as contraindicated for MRI. History of gunshot wound. Circumstances or conditions that may interfere with magnetic resonance imaging (MRI) Inability to complete the baseline study procedures within four hours and/or correctly, as determined by the PI.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania

Philadelphia, United StatesOpen Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania in Google Maps
CompletedOne Study Center